my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
01-02-2012: The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include innovative biofunctional polymers. The project is designed to simplify the administration of biopharmaceuticals and to improve their bioavailability. PeTrA is managed by a consortium consisting of Evonik Industries AG, Merck KGaA, EMC microcollections GmbH, a high-tech company for peptide and peptidomimetics synthesis, the Helmholtz Center for Infection Research (HZI), and the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB).
The project, which started on July 1, 2011, is scheduled to last for three years. Approximately half of the 6 million Euro budget is supported by the three industry partners. The PeTrA consortium also includes the Friedrich Schiller University in Jena, the Saarland University, the University of Nijmegen (Netherlands), the Bonn University Hospital, the Charité Hospital Berlin, the Kiel University, and the Würzburg University.
Biopharmaceuticals have been on the advance for years in modern drug therapy. They include peptides, proteins and antibodies, nucleic acids and blood components that represent a promising basis for new active principles and for cancer immunotherapy. Many of these highly successful drugs improve patient life quality and have enormous technological potential for the pharmaceutical industry.
Today, biopharmaceuticals are mostly administered by injection. Indeed, there is no efficient or broadly applicable system for administering them via the mouth (oral) or through the respiratory pathways (inhalation) because they are not easily absorbed by the mucous membranes of the gastrointestinal tract and respiration system, and tend to be degraded in the stomach before they can have an effect on the body. The PeTrA project aims at overcoming these obstacles by packaging highly sensitive biopharmaceuticals into nano- and micro-sized particles that transport the active ingredients through the mucous membranes and protect them from degradation in the stomach.
“Tablets and sprays are more convenient for patients, particularly in long-term therapies which can require continuous drug intake over weeks or months,” says Dr. Rosario Lizio about the motivation of the research partners. Lizio, the PeTrA project coordinator, is also the head of the Discovery & Development department of Pharma Polymers, a product line of the Health Care Business Line of Evonik specialized in drug delivery systems.
“I am convinced that the breadth of expertise represented in the project provides an excellent basis for the development of novel drug delivery technologies for biopharmaceuticals.” says Lizio. “The team composition combines leading competencies in the design of pharmaceutical functional polymers, formulation of drug release systems as well as innovative models to assess the in-vivo efficacy of these systems. I am delighted to be part of this venture and look forward to contributing Evonik’s expertise in functional pharmaceutical polymer design and formulation” he adds.
*PeTrA stands for “Platform for efficient epithelial transport of pharmaceutical applications with innovative particular carrier systems” and is part of the BMBF grant project “Efficient drug transport in biological systems - BioMatVital: Biotransporters.“
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Jülich researchers contribute to "Human Brain Project"
To understand the human brain using simulation – that’s the vision of the Human Brain Project (HBP). In order to make it a reality, researchers from 23 countries are working together to build a unique infrastructure that will allow them to establish and further develop a brain research and ... more
BRAIN to lead the NatLifE 2020 industrial innovation alliance
BRAIN AG has announced that the Natural Life Excellence Network 2020 (NatLifE 2020) innovation alliance will be funded by the Federal Ministry of Education and Research (BMBF) under the “Industrial Biotechnology Innovation Initiative” scheme. The official announcement has been made by Perma ... more
Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin Program
Pieris AG announced the receipt of a EUR 1 million grant to support the development of the company’s proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and metastasis. The goal of the funded research will be to delineate a biomarker ... more
Bundesministerium für Bildung und Forschung (BMBF)
Education forms the basis for one's whole life; research opens up previously unknown opportunities in all fields of life. Education and research need perspectives which extend far into the future. These are the foundations on which our future evolves. The BMBF's promotion of education and r ... more
Evonik selects OPX Biotechnologies for joint development of bio-based chemicals
OPX Biotechnologies, Inc. (OPXBIO) and Evonik Industries AG announced the two companies have entered into an agreement to jointly develop certain bio-based specialty chemicals. The joint-development agreement signed May 3rd 2013 calls for OPXBIO to use its proprietary EDGE™ (Efficiency Dir ... more
Evonik invests heavily in biotech
Evonik Industries plans to continue expanding its commitment to biotechnology. “Biotech opens up interesting opportunities for profitable growth in a range of business areas,” says Patrik Wohlhauser, a member of the Executive Board. “It’s also giving Evonik’s growth strategy a stronger focu ... more
Evonik Industries and BRAIN co-operate
Evonik Industries AG and BRAIN AG co-operate in the field of the development of novelmicroorganisms with unique, selective binding- and adsorption characteristics on selected surfaces. Within the co-operation the partners pursue the joint objective of identifying and developing suitable mic ... more
Merck’s credit rating raised by Standard & Poor’s to ‘A’
Standard & Poor’s announced that it raised Merck's long- and short-term corporate credit and issue ratings to “A/A-1” from “A-/A-2”. The outlook is stable. Standard & Poor’s noted in its report: “The upgrade reflects our view that Merck’s credit metrics have continued to improve.” In March ... more
Frost & Sullivan commends Merck Serono for its excellence in product differentiation
Merck Serono announced that based on its recent analysis of the human growth hormones (HGH) market, Frost & Sullivan recognises Merck Serono with the 2013 Europe Product Differentiation Excellence Award. “Merck Serono is lauded for its cutting-edge drug delivery devices - easypod® and cool. ... more
Sixth Merck Serono spin-off company to focus on gastrointestinal immunological disorders
Merck Serono announced the creation of Calypso Biotech, the sixth spin-off company resulting from its Entrepreneur Partnership Program (EPP). Calypso Biotech was formed around Merck Serono’s R&D portfolio in the field of inflammatory bowel diseases, targeting selected niche indications with ... more
New SeQuant® ZIC®-cHILIC HPLC columns from Merck Millipore
SeQuant® ZIC®-cHILIC: a revolutionary HPLC column specially designed for the separation of polar hydrophilic compounds. more
SeQuant® ZIC®-HILIC columns make analysis of complex food samples easier
If samples have to be analyzed for contamination with pesticides, fungicides or antibiotics, Merck Millipore offers special HPLC columns and tips more
Innovative Point-of-Use Water Purification Provided by Millipore's New Milli-Q® Integral System
The Milli-Q® Integral water purification system provides you with integrated, reliable lab-scale production of pure and ultrapure water more
Merck Millipore Introduces Unique Lab Water E-Solution: Millitrack® Compliance
This unique fully-embedded water purification system software has been developed especially for the pharmaceutical, biotech and contract labs more
Merck Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Th ... more
Merck Schuchardt OHG, a 100% subsidiary of Merck KGaA, Germany, has, for the last 135 years, been one of the leading German producers and suppliers of organic intermediates, fine chemicals, reagents and solvents for laboratories, medium-sized and bulk production. more
Together EMD Biosciences and Merck Chemicals Ltd. are the research reagents group of the Performance and Life Science Chemicals division of Merck KGaA. Merck KGaA was founded in 1668 in Darmstadt, Germany, and now has more than 29,000 employees in 53 countries. more
BMBF PeTrA Project to make administration of biopharmaceuticals more tolerable for patients
The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include inn ... more
AFFiRiS atherosclerosis vaccine development receives EU support
AFFiRiS AG announced that its atherosclerosis vaccine development program is receiving support from the EU's EUROTRANS-BIO call. The supported project - known as CETP Vaccine (ETB-2008-28) - is based on the AFFITOME® technology of AFFiRiS AG and is being conducted together with EMC microcol ... more
Neuer Forschungsverbund entwickelt biokatalytische Verfahren zur Aktivierung von Kohlenwasserstoffen
Die BRAIN AG gibt den Abschluss eines Kooperationsvertrages mit den Hochschulgruppen um Prof. Dr. Andreas Schmid, Universität Dortmund, PD Dr. Jürgen Pleiss, Universität Stuttgart, Prof. Dr. Ulrich Schwaneberg, International University Bremen, der EMC microcollections GmbH und einem führend ... more
A protein called c-FLIP-R is critical to immune cell survival: If this molecule is missing, the cells kill themselves – and are thus no longer able to perform their job fighting off invaders. Apoptosis, programmed cell death, is a kind of cellular suicide program. If something triggers it, ... more
The protein C4BP is similar to a spider in its spatial form with eight “arms”. The structure of the “spider body” has recently been described in detail by researchers from the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Technische Universität Darmstadt. This leads ... more
American biochemist to receive this year's Inhoffen Medal
How do bacteria cope when exposed to toxic mercury, how are they able to outlast antibiotics, and how can they be killed using so-called "suicide inhibitors?" These are but a few of the many research topics US biochemist Christopher Walsh has devoted his career as a scientist to. Walsh will ... more
Helmholtz-Zentrum für Infektionsforschung GmbH
As a Helmholtz centre for infectious diseases, the main focus of the GBF research activities is to study microbial virulence factors, host-pathogen interactions, and immunity to develop strategies for the diagnosis, prevention and therapy of human infectious diseases. In addition, the GBF B ... more
Helmholtz-Zentrum für Infektionsforschung GmbH
How do bacteria, viruses, parasites and fungi make us sick? How does our immune system defend our body? These are the questions we at the HZI want to answer. Our goal: To set up the basis for new diagnostic tools, new active agents and new therapies against infectious diseases. Together wi ... more
BMBF PeTrA Project to make administration of biopharmaceuticals more tolerable for patients
The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include inn ... more
First biogeneric therapeutic protein from Fraunhofer Institute introduced to the market
Interferon-beta is used for multiple sclerosis therapy. An interferon-beta protein developed at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart, Germany, in collaboration with CinnaGen company, Tehran, Iran, is now the first therapeutic protein from a F ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
